Adrian Grenier Named Chief Earth Advocate for World View
31.3.2022 18:00:00 EEST | Business Wire | Press release
World View, the leading stratospheric ballooning and space tourism company, today announced environmentalist, actor, and UN Environment Goodwill Ambassador Adrian Grenier has been named its Chief Earth Advocate. In this new role he will support World View’s mission to rediscover Earth, inspiring new perspectives on the planet and encouraging deeper respect for it as a living organism. Today’s announcement follows the company’s entry into the space tourism and exploration market offering an affordable, long duration and accessible space experience on Earth.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20220331005341/en/
Adrian Grenier, World View Chief Earth Advocate (Photo credit: Courtesy of World View)
World View designed its space tourism experience based on the company’s business purpose: World View exists to inspire, create, and explore new perspectives for a radically improved future. The company believes its space tourism experience provides customers with an “awe inspiring” journey, from the time spent at one of World View’s spaceports to the time spent at the edge of space. World View is on a mission to deliver this transformative moment to a critical mass of humans knowing that it could lead to a markedly improved future for our fragile planet.
In his new role, Grenier will collaborate with World View’s leadership to ideate and develop strategies to ensure the company's sustainability goals are met through global partnerships, programming, and initiatives. He will also contribute to the development of its environmental strategy while playing a key role in helping participants understand their individual relationship to the planet as they prepare for and reflect on their trip.
"Adrian’s history as an eco-activist speaks for itself. World View is happy to welcome Adrian as our Chief Earth Advocate. Our main goal is to enable customers to see the beauty of the Earth we inhabit so we can radically improve the future of our own planet. Adrian is an excellent advocate and will help us in our mission,” said Ryan Hartman, President and CEO of World View.
Conservation has long been at the heart of Grenier’s social activism. In 2017, he helped the UN Environment Programme launch Clean Seas, a campaign to end marine plastic pollution. He also supported Wild for Life, advocating for the conservation of sawfish. The Lonely Whale Foundation, which he co-founded, strives to inspire empathy towards marine species and develop lifelong advocates for ocean health. Its innovative StopSucking campaign aims to discourage the use of single-use plastic straws, which are particularly harmful to marine wildlife. Grenier actively supports organizations focused on habit-changing education.
“I am honored to serve as World View’s Chief Earth Advocate. The partnership allows me to use my platform to champion healthier, regenerative choices for the Earth. Space tourism is an exciting concept, and the fact that World View puts our interconnectedness squarely at the heart of exploration is in line with my personal values. Together, we will be able to honor the planet and encourage future generations to be better stewards of its resources and beauty,” said Adrian Grenier, Chief Earth Advocate of World View.
World View Mission: Rediscover Earth
World View’s global space tourism program will begin its first commercial flights in early 2024. Unlike any other space tourism company, World View plans to have flights depart from state-of-the-art spaceports located in iconic locations like the Grand Canyon and Great Barrier Reef, providing participants the opportunity to experience natural and man-made wonders from the ground and the edge of space.
Flights will lift eight participants and two World View crew members in a zero-pressure stratospheric balloon and pressurized space capsule to 100,000 feet altitude, nearly 23 miles into the stratosphere, for a life-changing experience that will last six to 12 hours with average flight duration between six and eight hours. Participants will lift off before dawn to watch the sunrise over Earth, view the curvature of our planet and experience the darkness of space. They will see a world without borders, without race and will fully experience and immerse themselves in the beauty, fragility, history, and importance of the areas surrounding each location and of the Earth itself.
ABOUT WORLD VIEW
World View is the leading stratospheric exploration company on a mission to inspire the global community to rediscover Earth. Through both its legacy Stratollite imaging and newly launched space tourism and exploration businesses, World View is working to ensure its ultimate objective: honor the planet so that future generations will feel blessed to call it home. For more information, visit worldview.space.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20220331005341/en/
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Phase 3 RAINIER Results Supporting Best-in-Class Potential of Povetacicept in IgA Nephropathy Published in the New England Journal of Medicine and Presented at the American Society of Nephrology Kidney Week 202623.10.2026 20:42:00 EEST | Press release
Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced the publication of Phase 3 RAINIER results for povetacicept in the New England Journal of Medicine (NEJM), presentation of these data at the American Society of Nephrology (ASN) Kidney Week 2026 in Denver, Colorado, and advancement of the povetacicept clinical research program in IgAN. Vertex will also host an investor event during ASN on October 23 at 6:15-7 p.m. MDT (8:15-9 p.m. EDT). Further details are below. Data being presented include a pre-specified Week 36 interim analysis of the ongoing Phase 3 RAINIER trial of povetacicept, an engineered fusion protein and dual inhibitor of the BAFF (B cell activating factor) and APRIL (a proliferation inducing ligand) cytokines, in immunoglobulin A nephropathy (IgAN). RAINIER met its primary endpoint, with povetacicept achieving a 52.0% reduction from baseline in proteinuria at Week 36 and a statistically significant and clinically meaningful 49.8% reduction versus placebo (
Lifezone Metals Confirms Advanced Negotiations with Orion CMC on Kabanga Nickel Project23.10.2026 17:19:00 EEST | Press release
Lifezone Metals Limited (NYSE: LZM) notes comments made today by Oskar Lewnowski, Founder and Group Chief Executive of Orion Resource Partners, in an interview with Bloomberg Television regarding the Company’s Kabanga Nickel Project in Tanzania. In response to inbound inquiries from media outlets and investors following the interview, the Company can confirm that negotiations with Orion Critical Mineral Consortium (Orion CMC) regarding a significant equity investment into the Kabanga Nickel Project are at an advanced stage. The Orion CMC is a global investment platform launched by Orion Resource Partners in partnership with the U.S. International Development Finance Corporation (DFC) and Abu Dhabi's sovereign investor ADQ. As previously announced, the Company has been running a competitive process, led by Standard Chartered Bank, to secure a strategic investment into the Kabanga Nickel Project. Social Media LinkedIn | X | YouTube About Lifezone Metals Lifezone Metals (NYSE: LZM) is com
BeOne Medicines Reports Sustained Survival Benefit with TEVIMBRA-ZIIHERA Combination in First-Line HER2+ Gastroesophageal Cancer23.10.2026 17:15:00 EEST | Press release
BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced new survival results from the planned second interim analysis (IA2) and final formal analysis of the Phase 3 HERIZON-GEA-01 trial, further confirming the benefit of TEVIMBRA® (tislelizumab) plus ZIIHERA® (zanidatamab) and chemotherapy as first-line treatment for patients with HER2-positive locally advanced or metastatic gastroesophageal adenocarcinoma (GEA). The results will be presented today as a late-breaking abstract during a rapid oral session at the European Society for Medical Oncology (ESMO) Congress 2026 in Madrid, Spain (LBA79). Mark Lanasa, M.D., Ph.D., Chief Medical Officer, Solid Tumors at BeOne, said: “Following the U.S. approval in August, these longer-term data provide further evidence supporting TEVIMBRA plus ZIIHERA and chemotherapy as the new standard of care in all first-line HER2-positive advanced gastroesophageal adenocarcinoma patients, regardless of PD-L1 sta
inDrive and Pony.ai Announce Collaboration to Explore Autonomous Mobility in Kazakhstan Built on NVIDIA Hyperion23.10.2026 16:00:00 EEST | Press release
inDrive, the global mobility and delivery platform, today announced it has signed a memorandum of understanding (MOU) with NVIDIA and Pony.ai, a global leader in the large-scale commercialization of autonomous driving technology, to explore the future of autonomous ride-hailing. Kazakhstan will serve as the first test market. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261023143469/en/ inDrive partners with Pony.ai and NVIDIA to explore autonomous mobility in Kazakhstan Kazakhstan was chosen first for its regulatory readiness following the creation of the country’s first structured legal framework for driverless transport, as part of its “Year of Digitalization and Artificial Intelligence.” Combined with Kazakhstan’s position as a leading Central Asian economy, this gives the companies a clear basis to assess autonomous ride-hailing in practice. The three companies will evaluate the technical, operational, regulatory and
Brenus Pharma's Novel In Vivo Immunotherapy STC-1010 Shows Safety, Activating T Cells in First-Line MSS Metastatic Colorectal Cancers With 2 Complete Responses.23.10.2026 15:50:00 EEST | Press release
Brenus Pharma, a clinical-stage biotech company, announced first data from the Phase Ia dose escalation of BreAK CRC-001. Nine unresectable patients were treated; 89% had liver metastases and 89% KRAS-mutant tumors, a population refractory to immunotherapy. Median follow-up: 8 months (1–14; data cut-off 6/08/2026). 95% of metastatic colorectal cancers are pMMR/MSS tumors, poorly immunogenic and resistant to immunotherapy. STC-1010, the company’s lead in vivo DC-engager, is designed to make these “cold” tumors visible to immune cells. Safety: no dose-limiting toxicity, only grade 1–2 related adverse events. Clinical activity (seven evaluable patients, RECIST 1.1): 100% disease control, 57% objective response rate (4/7). 43% of patients became operable (3/7): two with no evidence of disease afterward. Molecular profile: ctDNA dropped by up to 97% within two months, TP53 and KRAS mutations near undetectable. Immune activity (first six patients): STC-1010 regimen nearly quadrupled cytotoxi
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
